Insulin resistance in clinical and experimental alcoholic liver disease

Annals of the New York Academy of Sciences

Volumn 1353, Issue 1, 2015, Pages 1-20

  Carr, Rotonya M ^a   Correnti, Jason ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Alcoholic liver disease; Insulin resistance; Metabolic syndrome; NAFLD NASH; Steatohepatitis

Indexed keywords

2 [4 [2 [3 CYCLOHEXYL 1 (4 CYCLOHEXYLBUTYL)UREIDO]ETHYL]PHENYLTHIO] 2 METHYLPROPIONIC ACID; 5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; ADIPONECTIN; ALCOHOL; GLITAZONE DERIVATIVE; GLUCAGON; GLUCOSE TRANSPORTER; INSULIN; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; LEPTIN; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE; PIOGLITAZONE; PIRINIXIC ACID; PROTEIN KINASE B; RESVERATROL; ROSIGLITAZONE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRANSCRIPTION FACTOR FKHR; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; TUROFEXORATE ISOPROPYL; UNINDEXED DRUG;

ALCOHOL ABSTINENCE; ALCOHOL CONSUMPTION; ALCOHOL LIVER CIRRHOSIS; ALCOHOL LIVER DISEASE; ALCOHOLIC FATTY LIVER; ALCOHOLISM; ARTICLE; CARBOHYDRATE DIET; CHRONIC HEPATITIS C; DRUG MECHANISM; ENZYME ACTIVATION; EPIDEMIOLOGICAL DATA; EXPERIMENTAL ALCOHOLIC LIVER DISEASE; EXPERIMENTAL HEPATITIS; FATTY ACID BLOOD LEVEL; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLYCOGEN SYNTHESIS; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; IMPAIRED GLUCOSE TOLERANCE; IN VITRO STUDY; IN VIVO STUDY; INSULIN CLEARANCE; INSULIN DEFICIENCY; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN RESPONSE; INSULIN SENSITIVITY; INTESTINE FLORA; INTRACELLULAR SIGNALING; LIPID METABOLISM; LIVER FIBROSIS; LIVER HISTOLOGY; NONALCOHOLIC FATTY LIVER; NONHUMAN; PANCREAS ISLET BETA CELL; PORTAL HYPERTENSION; SINGLE NUCLEOTIDE POLYMORPHISM; ANIMAL; FEMALE; MALE; METABOLISM; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; FEMALE; HUMANS; INSULIN; INSULIN RESISTANCE; LIVER DISEASES, ALCOHOLIC; MALE; SIGNAL TRANSDUCTION;

EID: 84945484423     PISSN: 00778923     EISSN: 17496632     Source Type: Journal    
DOI: 10.1111/nyas.12787     Document Type: Article

References (176)

1. O'Shea, R.S., S. Dasarathy & A.J. McCullough . 2010. Alcoholic liver disease. Hepatology 51: 307-328.
2. Services, U.D.o.H.a.H. 2000. The economic costs of alcohol abuse. 10th Special Report to the US Congress on Alcohol and Health: Highlights from Current Research, 364-372.
3. Charlton, M.R. et al. 2011. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 141: 1249-1253.
4. Diehl, A.M. 1997. Alcoholic liver disease: natural history. Liver Transpl. Surg. 3: 206-211.
5. Raynard, B. et al. 2002. Risk factors of fibrosis in alcohol-induced liver disease. Hepatology 35: 635-638.
6. Alkerwi, A. et al. 2009. Alcohol consumption and the prevalence of metabolic syndrome: a meta-analysis of observational studies. Atherosclerosis 204: 624-635.
7. Zein, N.N. et al. 2000. Prevalence of diabetes mellitus in patients with end-stage liver cirrhosis due to hepatitis C, alcohol, or cholestatic disease. J. Hepatol. 32: 209-217.
8. Perry, R.J. et al. 2014. The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature 510: 84-91.
9. Muoio, D.M. & C.B. Newgard . 2008. Mechanisms of disease: molecular and metabolic mechanisms of insulin resistance and beta-cell failure in type 2 diabetes. Nat. Rev. Mol. Cell Biol. 9: 193-205.
10. Borai, A. et al. 2011. Selection of the appropriate method for the assessment of insulin resistance. BMC Med. Res. Methodol. 11: 158.
11. Carr, R.M. et al. 2013. Temporal effects of ethanol consumption on energy homeostasis, hepatic steatosis, and insulin sensitivity in mice. Alcohol Clin. Exp. Res. 37: 1091-1099.
12. Iversen, J., H. Vilstrup, & N. Tygstrup . 1984. Kinetics of glucose metabolism in relation to insulin concentrations in patients with alcoholic cirrhosis and in healthy persons. Gastroenterology 87: 1138-1143.
13. Shmueli, E. et al. 1993. Normal splanchnic but impaired peripheral insulin-stimulated glucose uptake in cirrhosis. Hepatology 18: 86-95.
14. DeFronzo, R.A. & D. Tripathy . 2009. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care 32: S157-S163.
15. Magnusson, J. & K.G. Tranberg . 1987. Impaired early insulin response to intravenous glucose in alcoholic liver cirrhosis. Scand. J. Gastroenterol. 22: 301-307.
16. Kruszynska, Y.T. et al. 1998. Insulin secretory capacity and the regulation of glucagon secretion in diabetic and non-diabetic alcoholic cirrhotic patients. J. Hepatol. 28: 280-291.
17. Donohue, T.M., N.A. Osna, & D.L. Clemens . 2006. Recombinant Hep G2 cells that express alcohol dehydrogenase and cytochrome P450 2E1 as a model of ethanol-elicited cytotoxicity. Int. J. Biochem. Cell Biol. 38: 92-101.
18. Wolfla, C.E., R.A. Ross, & D.W. Crabb . 1988. Induction of alcohol dehydrogenase activity and mRNA in hepatoma cells by dexamethasone. Arch. Biochem. Biophys. 263: 69-76.
19. Lea, M.A. 1993. Regulation of gene expression in hepatomas. Int. J. Biochem. 25: 457-469.
20. Nishitani, Y. et al. 2008. Ethanol-induced JNK activation suppressed via active Akt in hepatocytes. Nihon Arukoru Yakubutsu Igakkai Zasshi 43: 35-43.
21. Hoek, J.B., R. Rubin, & A.P. Thomas . 1988. Ethanol-induced phospholipase C activation is inhibited by phorbol esters in isolated hepatocytes. Biochem. J. 251: 865-871.
22. Leo, M.A. & C.S. Lieber . 1983. Hepatic fibrosis after long-term administration of ethanol and moderate vitamin A supplementation in the rat. Hepatology 3: 1-11.
23. Tsukamoto, H. et al. 1995. Experimental liver cirrhosis induced by alcohol and iron. J. Clin. Invest. 96: 620-630.
24. Mathews, S. et al. 2014. Animals models of gastrointestinal and liver diseases. Animal models of alcohol-induced liver disease: pathophysiology, translational relevance, and challenges. Am. J. Physiol. Gastrointest. Liver Physiol. 306: G819-G823.
25. Bergheim, I. et al. 2011. Alcoholic liver disease and exacerbation by malnutrition and infections: what animal models are currently available? Ann. N. Y. Acad. Sci. 1216: 41-49.
26. Lieber, C.S., D.P. Jones, & L.M. Decarli . 1965. Effects of prolonged ethanol intake: production of fatty liver despite adequate diets. J. Clin. Invest. 44: 1009-1021.
27. Lieber, C.S. & L.M. DeCarli . 1994. Animal models of chronic ethanol toxicity. Methods Enzymol. 233: 585-594.
28. Liangpunsakul, S. et al. 2012. Imipramine blocks ethanol-induced ASMase activation, ceramide generation, and PP2A activation, and ameliorates hepatic steatosis in ethanol-fed mice. Am. J. Physiol. Gastrointest. Liver Physiol. 302: G515-G523.
29. Onishi, Y. et al. 2003. Ethanol feeding induces insulin resistance with enhanced PI 3-kinase activation. Biochem. Biophys. Res. Commun. 303: 788-794.
30. de la Monte, S.M. et al. 2008. Insulin resistance in experimental alcohol-induced liver disease. J. Gastroenterol. Hepatol. 23: e477-486.
31. He, L. et al. 2007. Dose-dependent effects of alcohol on insulin signaling: partial explanation for biphasic alcohol impact on human health. Mol. Endocrinol. 21: 2541-2550.
32. Lang, C.H., Z. Derdak, & J.R. Wands . 2014. Strain-dependent differences for suppression of insulin-stimulated glucose uptake in skeletal and cardiac muscle by ethanol. Alcohol Clin. Exp. Res. 38: 897-910.
33. Yin, M. et al. 1999. Essential role of tumor necrosis factor alpha in alcohol-induced liver injury in mice. Gastroenterology 117: 942-952.
34. Ueno, A. et al. 2012. Mouse intragastric infusion (iG) model. Nat. Protoc. 7: 771-781.
35. Tsukamoto, H. et al. 1984. Long-term cannulation model for blood sampling and intragastric infusion in the rat. Am. J. Physiol. 247: R595-R599.
36. Zhao, L.N. et al. 2009. The diabetogenic effects of excessive ethanol: reducing beta-cell mass, decreasing phosphatidylinositol 3-kinase activity and GLUT-4 expression in rats. Br. J. Nutr. 101: 1467-1473.
37. Lindtner, C. et al. 2013. Binge drinking induces whole-body insulin resistance by impairing hypothalamic insulin action. Sci. Transl. Med. 5: 170ra14.
38. Pang, M. et al. 2009. PPARdelta agonist attenuates alcohol-induced hepatic insulin resistance and improves liver injury and repair. J. Hepatol. 50: 1192-1201.
39. DeNucci, S.M. et al. 2010. Rat strain differences in susceptibility to alcohol-induced chronic liver injury and hepatic insulin resistance. Gastroenterol. Res. Pract. 2010: 312790.
40. Tuma, D.J., C.A. Casey, & M.F. Sorrell . 1991. Chronic ethanol-induced impairments in receptor-mediated endocytosis of insulin in rat hepatocytes. Alcohol Clin. Exp. Res. 15: 808-813.
41. Patel, B.C. et al. 1991. Impairment of hepatic insulin receptors during chronic ethanol administration. Am. J. Physiol. 261: G199-G205.
42. Fawcett, J., B. Hammond, & G.D. Smith . 1993. Acute effects of ethanol on hepatic endocytosis and processing of insulin in perfused rat liver. Am. J. Physiol. 264: E420-E427.
43. Banerjee, K. et al. 1998. Ethanol inhibition of insulin signaling in hepatocellular carcinoma cells. Alcohol Clin. Exp. Res. 22: 2093-2101.
44. Ramirez, T. et al. 2013. Insulin resistance, ceramide accumulation and endoplasmic reticulum stress in experimental chronic alcohol-induced steatohepatitis. Alcohol Alcohol 48: 39-52.
45. Alwahsh, S.M. et al. 2014. Combination of alcohol and fructose exacerbates metabolic imbalance in terms of hepatic damage, dyslipidemia, and insulin resistance in rats. PLoS One 9: e104220.
46. Bhavani, K. et al. 1995. Effect of ethanol on p36 protein kinase substrate and insulin receptor substrate 1 expression and tyrosyl phosphorylation in human hepatocellular carcinoma cells. Alcohol Clin. Exp. Res. 19: 441-446.
47. Schattenberg, J.M. et al. 2005. Hepatocyte CYP2E1 overexpression and steatohepatitis lead to impaired hepatic insulin signaling. J. Biol. Chem. 280: 9887-9894.
48. He, J., S. de la Monte, & J.R. Wands . 2007. Acute ethanol exposure inhibits insulin signaling in the liver. Hepatology 46: 1791-1800.
49. Lu, M. et al. 2012. Insulin regulates liver metabolism in vivo in the absence of hepatic Akt and Foxo1. Nat. Med. 18: 388-395.
50. He, L. et al. 2006. Chronic ethanol intake impairs insulin signaling in rats by disrupting Akt association with the cell membrane. Role of TRB3 in inhibition of Akt/protein kinase B activation. J. Biol. Chem. 281: 11126-11134.
51. Lieber, C.S. et al. 2008. Alcohol alters hepatic FoxO1, p53, and mitochondrial SIRT5 deacetylation function. Biochem. Biophys. Res. Commun. 373: 246-252.
52. Wang, Y. et al. 2013. Elevated expression of forkhead box protein O1 (FoxO1) in alcohol-induced intestinal barrier dysfunction. Acta Histochem. 115: 557-563.
53. Adachi, M. et al. 2007. The forkhead transcription factor FoxO1 regulates proliferation and transdifferentiation of hepatic stellate cells. Gastroenterology 132: 1434-1446.
54. Lee, J. & M.S. Kim . 2007. The role of GSK3 in glucose homeostasis and the development of insulin resistance. Diabetes Res. Clin. Pract. 77(Suppl. 1): S49-S57.
55. Bourogaa, E. et al. 2013. Antioxidant activity and hepatoprotective potential of Hammada scoparia against ethanol-induced liver injury in rats. J. Physiol. Biochem. 69: 227-237.
56. Meng, Z. et al. 2013. Alteration of 11β-hydroxysteroid dehydrogenase type 1 and glucocorticoid receptor by ethanol in rat liver and mouse hepatoma cells. J. Diabetes Res. 2013: 218102.
57. Lefevre, A., H. Adler, & C.S. Lieber . 1970. Effect of ethanol on ketone metabolism. J. Clin. Invest. 49: 1775-1782.
58. Carr, R.M. et al. 2014. Absence of perilipin 2 prevents hepatic steatosis, glucose intolerance and ceramide accumulation in alcohol-fed mice. PLoS One 9: e97118.
59. Liu, J. 2014. Ethanol and liver: recent insights into the mechanisms of ethanol-induced fatty liver. World J. Gastroenterol. 20: 14672-14685.
60. You, M. & D.W. Crabb . 2004. Molecular mechanisms of alcoholic fatty liver: role of sterol regulatory element-binding proteins. Alcohol 34: 39-43.
61. Brown, M.S. & J.L. Goldstein . 2008. Selective versus total insulin resistance: a pathogenic paradox. Cell Metab. 7: 95-96.
62. Ahima, R.S. & S.Y. Osei . 2008. Adipokines in obesity. Front. Horm. Res. 36: 182-197.
63. Feng, B., T. Zhang, & H. Xu . 2013. Human adipose dynamics and metabolic health. Ann. N. Y. Acad. Sci. 1281: 160-177.
64. Marra, F. & C. Bertolani . 2009. Adipokines in liver diseases. Hepatology 50: 957-969.
65. Ahima, R.S. & J.S. Flier . 2000. Leptin. Annu. Rev. Physiol. 62: 413-437.
66. Pelleymounter, M.A. et al. 1995. Effects of the obese gene product on body weight regulation in ob/ob mice. Science 269: 540-543.
67. Tan, X. et al. 2012. Leptin deficiency contributes to the pathogenesis of alcoholic fatty liver disease in mice. Am. J. Pathol. 181: 1279-1286.
68. Dunn, W. et al. 2005. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology 41: 353-358.
69. Rachakonda, V. et al. 2014. Stratification of risk of death in severe acute alcoholic hepatitis using a panel of adipokines and cytokines. Alcohol. Clin. Exp. Res. 38: 2712-2721.
70. Shklyaev, S. et al. 2003. Sustained peripheral expression of transgene adiponectin offsets the development of diet-induced obesity in rats. Proc. Natl. Acad. Sci. U.S.A. 100: 14217-14222.
71. Rogers, C.Q., J.M. Ajmo, & M. You . 2008. Adiponectin and alcoholic fatty liver disease. IUBMB Life 60: 790-797.
72. Kadowaki, T. & T. Yamauchi . 2005. Adiponectin and adiponectin receptors. Endocr. Rev. 26: 439-451.
73. You, M. et al. 2005. Role of adiponectin in the protective action of dietary saturated fat against alcoholic fatty liver in mice. Hepatology 42: 568-577.
74. Xu, A. et al. 2003. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J. Clin. Invest. 112: 91-100.
75. Chen, X., B.M. Sebastian, & L.E. Nagy . 2007. Chronic ethanol feeding to rats decreases adiponectin secretion by subcutaneous adipocytes. Am. J. Physiol. Endocrinol. Metab. 292: E621-E628.
76. Song, Z. et al. 2008. Inhibition of adiponectin production by homocysteine: a potential mechanism for alcoholic liver disease. Hepatology 47: 867-879.
77. Esfandiari, F. et al. 2007. S-adenosylmethionine attenuates hepatic lipid synthesis in micropigs fed ethanol with a folate-deficient diet. Alcohol Clin. Exp. Res. 31: 1231-1239.
78. Ajmo, J.M. et al. 2008. Resveratrol alleviates alcoholic fatty liver in mice. Am. J. Physiol. Gastrointest. Liver Physiol. 295: G833-G842.
79. Xu, J. et al. 2011. Synergistic steatohepatitis by moderate obesity and alcohol in mice despite increased adiponectin and p-AMPK. J. Hepatol. 55: 673-682.
80. Correnti, J.M. et al. 2014. Pharmacological ceramide reduction alleviates alcohol-induced steatosis and hepatomegaly in adiponectin knockout mice. Am. J. Physiol. Gastrointest. Liver Physiol. 306: G959-G973.
81. Buechler, C. et al. 2009. Elevated adiponectin serum levels in patients with chronic alcohol abuse rapidly decline during alcohol withdrawal. J. Gastroenterol. Hepatol. 24: 558-563.
82. Kasztelan-Szczerbinska, B. et al. 2013. Association of serum adiponectin, leptin, and resistin concentrations with the severity of liver dysfunction and the disease complications in alcoholic liver disease. Mediators Inflamm. 2013: 148526.
83. 2+-independent protein kinase C activation in cultured rat hepatic stellate cells. Alcohol Clin. Exp. Res. 23: 279-284.
84. Grunnet, N. et al. 1985. Effect of ethanol on fatty acid metabolism in cultured hepatocytes: dependency on incubation time and fatty acid concentration. Alcohol 2: 157-161.
85. Grosch, S., S. Schiffmann, & G. Geisslinger . 2012. Chain length-specific properties of ceramides. Prog. Lipid Res. 51: 50-62.
86. Bikman, B.T. & S.A. Summers . 2011. Ceramides as modulators of cellular and whole-body metabolism. J. Clin. Invest. 121: 4222-4230.
87. Turban, S. & E. Hajduch, 2011. Protein kinase C isoforms: mediators of reactive lipid metabolites in the development of insulin resistance. FEBS Lett. 585: 269-274.
88. Powell, D.J. et al. 2003. Ceramide disables 3-phosphoinositide binding to the pleckstrin homology domain of protein kinase B (PKB)/Akt by a PKCzeta-dependent mechanism. Mol. Cell. Biol. 23: 7794-7808.
89. Dobrowsky, R.T. et al. 1993. Ceramide activates heterotrimeric protein phosphatase 2A. J. Biol. Chem. 268: 15523-15530.
90. Deaciuc, I.V. et al. 2000. Apoptosis and dysregulated ceramide metabolism in a murine model of alcohol-enhanced lipopolysaccharide hepatotoxicity. Alcohol Clin. Exp. Res. 24: 1557-1565.
91. Liangpunsakul, S. et al. 2010. Inhibitory effect of ethanol on AMPK phosphorylation is mediated in part through elevated ceramide levels. Am. J. Physiol. Gastrointest. Liver Physiol. 298: G1004-G1012.
92. Clugston, R.D. et al. 2011. Altered hepatic lipid metabolism in C57BL/6 mice fed alcohol: a targeted lipidomic and gene expression study. J. Lipid Res. 52: 2021-2031.
93. Zhao, Z. et al. 2011. Ethanol-induced alterations in fatty acid-related lipids in serum and tissues in mice. Alcohol Clin. Exp. Res. 35: 229-234.
94. Lizarazo, D. et al. 2013. Ceramide inhibitor myriocin restores insulin/insulin growth factor signaling for liver remodeling in experimental alcohol-related steatohepatitis. J. Gastroenterol. Hepatol. 28: 1660-1668.
95. Kang, L. et al. 2007. Chronic ethanol and triglyceride turnover in white adipose tissue in rats: inhibition of the anti-lipolytic action of insulin after chronic ethanol contributes to increased triglyceride degradation. J. Biol. Chem. 282: 28465-28473.
96. Watson, M.L., M. Coghlan, & H.S. Hundal . 2009. Modulating serine palmitoyl transferase (SPT) expression and activity unveils a crucial role in lipid-induced insulin resistance in rat skeletal muscle cells. Biochem. J. 417: 791-801.
97. Varela, G.M. et al. 2008. Inhibition of ADRP prevents diet-induced insulin resistance. Am. J. Physiol. Gastrointest. Liver Physiol. 295: G621-G628.
98. Holland, W.L. et al. 2011. Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat. Med. 17: 55-63.
99. Garcia-Ruiz, C. et al. 2015. Acid sphingomyelinase-ceramide system in steatohepatitis: a novel target regulating multiple pathways. J. Hepatol. 62: 219-233.
100. Friedrich, K. et al. 2014. PNPLA3 in end-stage liver disease: alcohol consumption, hepatocellular carcinoma development, and transplantation-free survival. J. Gastroenterol. Hepatol. 29: 1477-1484.
101. Romeo, S. et al. 2008. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 40: 1461-1465.
102. Dongiovanni, P. et al. 2013. PNPLA3 I148M polymorphism and progressive liver disease. World J. Gastroenterol. 19: 6969-6978.
103. Tian, C. et al. 2010. Variant in PNPLA3 is associated with alcoholic liver disease. Nat. Genet. 42: 21-23.
104. Stickel, F. et al. 2011. Genetic variation in the PNPLA3 gene is associated with alcoholic liver injury in caucasians. Hepatology 53: 86-95.
105. Huang, Y. et al. 2010. A feed-forward loop amplifies nutritional regulation of PNPLA3. Proc. Natl. Acad. Sci. U.S.A. 107: 7892-7897.
106. Wilson, P.A. et al. 2006. Characterization of the human patatin-like phospholipase family. J. Lipid Res. 47: 1940-1949.
107. Stickel, F. & J. Hampe . 2012. Genetic determinants of alcoholic liver disease. Gut 61: 150-159.
108. He, S. et al.2010. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J. Biol. Chem. 285: 6706-6715.
109. Qiao, A. et al. 2011. Mouse patatin-like phospholipase domain-containing 3 influences systemic lipid and glucose homeostasis. Hepatology 54: 509-521.
110. Chen, W. et al. 2010. Patatin-like phospholipase domain-containing 3/adiponutrin deficiency in mice is not associated with fatty liver disease. Hepatology 52: 1134-1142.
111. Basantani, M.K. et al. 2011. Pnpla3/Adiponutrin deficiency in mice does not contribute to fatty liver disease or metabolic syndrome. J. Lipid Res. 52: 318-329.
112. Palmer, N.D. et al. 2013. Characterization of European ancestry nonalcoholic fatty liver disease-associated variants in individuals of African and Hispanic descent. Hepatology 58: 966-975.
113. Dupont, N. et al. 2014. Neutral lipid stores and lipase PNPLA5 contribute to autophagosome biogenesis. Curr. Biol. 24: 609-620.
114. Peter, A. et al. 2014. PNPLA3 variant I148M is associated with altered hepatic lipid composition in humans. Diabetologia 57: 2103-2107.
115. Parlesak, A. et al. 2000. Increased intestinal permeability to macromolecules and endotoxemia in patients with chronic alcohol abuse in different stages of alcohol-induced liver disease. J. Hepatol. 32: 742-747.
116. Thakur, V. et al. 2006. Adiponectin normalizes LPS-stimulated TNF-alpha production by rat Kupffer cells after chronic ethanol feeding. Am. J. Physiol. Gastrointest. Liver Physiol. 290: G998-G1007.
117. Mutlu, E.A. et al. 2012. Colonic microbiome is altered in alcoholism. Am. J. Physiol. Gastrointest. Liver Physiol. 302: G966-G978.
118. Mutlu, E. et al. 2009. Intestinal dysbiosis: a possible mechanism of alcohol-induced endotoxemia and alcoholic steatohepatitis in rats. Alcohol. Clin. Exp. Res. 33: 1836-1846.
119. Chen, Y. et al. 2011. Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology 54: 562-572.
120. Keshavarzian, A. et al. 2001. Preventing gut leakiness by oats supplementation ameliorates alcohol-induced liver damage in rats. J. Pharmacol. Exp. Ther., 299: 442-448.
121. Tang, Y. et al. 2009. Oats supplementation prevents alcohol-induced gut leakiness in rats by preventing alcohol-induced oxidative tissue damage. J. Pharmacol. Exp. Ther. 329: 952-958.
122. Forsyth, C.B. et al. 2009. Lactobacillus GG treatment ameliorates alcohol-induced intestinal oxidative stress, gut leakiness, and liver injury in a rat model of alcoholic steatohepatitis. Alcohol 43: 163-172.
123. Rachakonda, V. et al. 2014. Serum metabolomic profiling in acute alcoholic hepatitis identifies multiple dysregulated pathways. PLoS One 9: e113860.
124. National Institute on Alcohol Abuse and Alcoholism (U.S.). 2005. Alcohol Alert. 66.
125. Watson, C.G. 1987. Recidivism in "controlled drinker" alcoholics: a longitudinal study. J. Clin. Psychol. 43: 404-412.
126. Zhang, X. et al. 2014. Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes. Hepatology 60: 2008-2016.
127. Lee, J.M. et al. 2010. AMPK-dependent repression of hepatic gluconeogenesis via disruption of CREB.CRTC2 complex by orphan nuclear receptor small heterodimer partner. J. Biol. Chem. 285: 32182-32191.
128. Zhu, Z. et al. 2014. Involvement of insulin resistance in the protective effect of metformin against alcoholic liver injury. Alcohol. Clin. Exp. Res. 38: 1510-1519.
129. Bergheim, I. et al. 2006. Metformin prevents alcohol-induced liver injury in the mouse: critical role of plasminogen activator inhibitor-1. Gastroenterology 130: 2099-2112.
130. You, M. et al. 2004. The role of AMP-activated protein kinase in the action of ethanol in the liver. Gastroenterology 127: 1798-1808.
131. Tomita, K. et al. 2005. AICAR, an AMPK activator, has protective effects on alcohol-induced fatty liver in rats. Alcohol Clin. Exp. Res. 29: 240S-245S.
132. Enomoto, N. et al. 2003. Prevention of ethanol-induced liver injury in rats by an agonist of peroxisome proliferator-activated receptor-gamma, pioglitazone. J. Pharmacol. Exp. Ther. 306: 846-854.
133. Ohata, M. et al. 2004. Pioglitazone prevents acute liver injury induced by ethanol and lipopolysaccharide through the suppression of tumor necrosis factor-alpha. Alcohol Clin. Exp. Res. 28: 139S-144S.
134. Tomita, K. et al. 2004. Pioglitazone prevents alcohol-induced fatty liver in rats through up-regulation of c-Met. Gastroenterology 126: 873-885.
135. Shen, Z. et al. 2010. Involvement of adiponectin-SIRT1-AMPK signaling in the protective action of rosiglitazone against alcoholic fatty liver in mice. Am. J. Physiol. Gastrointest. Liver Physiol. 298: G364-G374.
136. Kersten, S. et al. 1999. Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J. Clin. Invest. 103: 1489-1498.
137. Kong, L. et al. 2011. Activation of peroxisome proliferator activated receptor alpha ameliorates ethanol induced steatohepatitis in mice. Lipids Health Dis. 10: 246.
138. de la Monte, S.M. et al. 2011. Peroxisome proliferator-activated receptor agonist treatment of alcohol-induced hepatic insulin resistance. Hepatol. Res. 41: 386-398.
139. Ramirez, T. et al. 2013. Chronic alcohol-induced hepatic insulin resistance and endoplasmic reticulum stress ameliorated by peroxisome-proliferator activated receptor-delta agonist treatment. J. Gastroenterol. Hepatol. 28: 179-187.
140. Holland, W.L. & P.E. Scherer . 2013. Cell biology. Ronning after the adiponectin receptors. Science 342: 1460-1461.
141. Yamauchi, T. et al. 2003. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423: 762-769.
142. Okada-Iwabu, M. et al. 2013. A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity. Nature 503: 493-499.
143. Mudaliar, S. et al. 2013. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 145: 574-582.e1.
144. Neuschwander-Tetri, B.A. et al. 2015. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385: 956-965.
145. Carr, R.M. & A.E. Reid . 2015. FXR Agonists as therapeutic agents for non-alcoholic fatty liver disease. Curr. Atheroscler. Rep. 17: 500.
146. Lefebvre, P. et al. 2009. Role of bile acids and bile acid receptors in metabolic regulation. Physiol. Rev. 89: 147-191.
147. Wu, W. et al. 2014. Activation of farnesoid X receptor attenuates hepatic injury in a murine model of alcoholic liver disease. Biochem. Biophys. Res. Commun. 443: 68-73.
148. Livero, F.A. et al. 2014. The FXR agonist 6ECDCA reduces hepatic steatosis and oxidative stress induced by ethanol and low-protein diet in mice. Chem. Biol. Interact. 217: 19-27.
149. 2015. Cited March 25, 2015. www.clinicaltrials.gov/ct2/show/NCT02039219.
150. Kotronen, A. & H. Yki-Jarvinen . 2008. Fatty liver: a novel component of the metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 28: 27-38.
151. Stepanova, M., N. Rafiq, & Z.M. Younossi . 2010. Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study. Gut 59: 1410-1415.
152. Stepanova, M. & Z.M. Younossi . 2012. Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clin. Gastroenterol. Hepatol. 10: 646-650.
153. Chalasani, N. et al. 2012. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55: 2005-2023.
154. Gao, B. & R. Bataller 2011. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology 141: 1572-1585.
155. Naveau, S. et al. 1997. Excess weight risk factor for alcoholic liver disease. Hepatology 25: 108-111.
156. Hart, C.L. et al. 2010. Effect of body mass index and alcohol consumption on liver disease: analysis of data from two prospective cohort studies. BMJ 340: c1240.
157. Iturriaga, H. et al. 1988. Overweight as a risk factor or a predictive sign of histological liver damage in alcoholics. Am. J. Clin. Nutr. 47: 235-238.
158. Loomba, R., R. Bettencourt, & E. Barrett-Connor . 2009. Synergistic association between alcohol intake and body mass index with serum alanine and aspartate aminotransferase levels in older adults: the Rancho Bernardo Study. Aliment. Pharmacol. Ther. 30: 1137-1149.
159. Minato, T. et al. 2014. Binge alcohol consumption aggravates oxidative stress and promotes pathogenesis of NASH from obesity-induced simple steatosis. Mol. Med. 20: 490-502.
160. Wang, Y., H.K. Seitz, & X.D. Wang . 2010. Moderate alcohol consumption aggravates high-fat diet induced steatohepatitis in rats. Alcohol. Clin. Exp. Res. 34: 567-573.
161. Nascimento, A.F. et al. 2013. Aggravation of nonalcoholic steatohepatitis by moderate alcohol consumption is associated with decreased SIRT1 activity in rats. Hepatobiliary Surg. Nutr. 2: 252-259.
162. French, S.W., K. Miyamoto, & H. Tsukamoto . 1986. Ethanol-induced hepatic fibrosis in the rat: role of the amount of dietary fat. Alcohol Clin. Exp. Res. 10: 13S-19S.
163. Tsukamoto, H. et al. 1986. Ethanol-induced liver fibrosis in rats fed high fat diet. Hepatology 6: 814-822.
164. Zong, H. et al. 2012. Cytochrome P-450 CYP2E1 knockout mice are protected against high-fat diet-induced obesity and insulin resistance. Am. J. Physiol. Endocrinol. Metab. 302: E532-E539.
165. Kim, H.J., M. Takahashi, & O. Ezaki . 1999. Fish oil feeding decreases mature sterol regulatory element-binding protein 1 (SREBP-1) by down-regulation of SREBP-1c mRNA in mouse liver. A possible mechanism for down-regulation of lipogenic enzyme mRNAs. J. Biol. Chem. 274: 25892-25898.
166. Xu, J. et al. 1999. Sterol regulatory element binding protein-1 expression is suppressed by dietary polyunsaturated fatty acids. A mechanism for the coordinate suppression of lipogenic genes by polyunsaturated fats. J. Biol. Chem. 274: 23577-23583.
167. Piquet, M.A. et al. 2004. Polyunsaturated fatty acid deficiency reverses effects of alcohol on mitochondrial energy metabolism. J. Hepatol. 41: 721-729.
168. You, M. et al. 2008. Mammalian sirtuin 1 is involved in the protective action of dietary saturated fat against alcoholic fatty liver in mice. J. Nutr. 138: 497-501.
169. Matsuzaka, T. et al. 2012. Elovl6 promotes nonalcoholic steatohepatitis. Hepatology 56: 2199-2208.
170. Zivkovic, A.M., J.B. German, & A.J. Sanyal . 2007. Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease. Am. J. Clin. Nutr. 86: 285-300.
171. Chen, P. et al. 2015. Supplementation of saturated long-chain fatty acids maintains intestinal eubiosis and reduces ethanol-induced liver injury in mice. Gastroenterology 148: 203-214.e16.
172. Kirpich, I.A. et al. 2012. The type of dietary fat modulates intestinal tight junction integrity, gut permeability, and hepatic toll-like receptor expression in a mouse model of alcoholic liver disease. Alcohol. Clin. Exp. Res. 36: 835-846.
173. Le Roy, T. et al. 2013. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut 62: 1787-1794.
174. Henao-Mejia, J. et al. 2012. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 482: 179-185.
175. Mezey, E. 1980. Alcoholic liver disease: roles of alcohol and malnutrition. Am. J. Clin. Nutr. 33: 2709-2718.
176. Lebrun, V. et al. 2013. Impact of PPAR-α induction on glucose homeostasis in alcohol-fed mice. Clin. Sci. (Lond.) 125: 501-511.